File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy.

TitleAn inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy.
Authors
KeywordsInflammatory response biomarker
Nomogram
Non-small cell lung cancer
Issue Date2018
PublisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccancer/
Citation
BMC Cancer, 2018, v. 18 n. 1, article no. 692 How to Cite?
AbstractBackground: Emerging inflammatory response biomarkers are developed to predict the survival of patients with cancer, the aim of our study is to establish an inflammation-related nomogram based on the classical predictive biomarkers to predict the survivals of patients with non-small cell lung cancer (NSCLC). Methods: Nine hundred and fifty-two NSCLC patients with lung cancer surgery performed were enrolled into this study. The cutoffs of inflammatory response biomarkers were determined by Receiver operating curve (ROC). Univariate and multivariate analysis were conducted to select independent prognostic factors to develop the nomogram. Results: The median follow-up time was 40.0 months (range, 1 to 92 months). The neutrophil to lymphocyte ratio (cut-off: 3.10, HR:1.648, P = 0.045) was selected to establish the nomogram which could predict the 5-year OS probability. The C-index of nomogram was 0.72 and the 5-year OS calibration curve displayed an optimal agreement between the actual observed outcomes and the predictive results. Conclusions: Neutrophil to lymphocyte ratio was shown to be a valuable biomarker for predicting survival of patients with NSCLC. The addition of neutrophil to lymphocyte ratio could improve the accuracy and predictability of the nomogram in order to provide reference for clinicians to assess patient outcomes.
Persistent Identifierhttp://hdl.handle.net/10722/260391
ISSN
2017 Impact Factor: 3.288
2015 SCImago Journal Rankings: 1.627
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWang, Y-
dc.contributor.authorQu, X-
dc.contributor.authorKam, NW-
dc.contributor.authorWang, K-
dc.contributor.authorShen, H-
dc.contributor.authorLiu, Q-
dc.contributor.authorDu, J-
dc.date.accessioned2018-09-14T08:40:58Z-
dc.date.available2018-09-14T08:40:58Z-
dc.date.issued2018-
dc.identifier.citationBMC Cancer, 2018, v. 18 n. 1, article no. 692-
dc.identifier.issn1471-2407-
dc.identifier.urihttp://hdl.handle.net/10722/260391-
dc.description.abstractBackground: Emerging inflammatory response biomarkers are developed to predict the survival of patients with cancer, the aim of our study is to establish an inflammation-related nomogram based on the classical predictive biomarkers to predict the survivals of patients with non-small cell lung cancer (NSCLC). Methods: Nine hundred and fifty-two NSCLC patients with lung cancer surgery performed were enrolled into this study. The cutoffs of inflammatory response biomarkers were determined by Receiver operating curve (ROC). Univariate and multivariate analysis were conducted to select independent prognostic factors to develop the nomogram. Results: The median follow-up time was 40.0 months (range, 1 to 92 months). The neutrophil to lymphocyte ratio (cut-off: 3.10, HR:1.648, P = 0.045) was selected to establish the nomogram which could predict the 5-year OS probability. The C-index of nomogram was 0.72 and the 5-year OS calibration curve displayed an optimal agreement between the actual observed outcomes and the predictive results. Conclusions: Neutrophil to lymphocyte ratio was shown to be a valuable biomarker for predicting survival of patients with NSCLC. The addition of neutrophil to lymphocyte ratio could improve the accuracy and predictability of the nomogram in order to provide reference for clinicians to assess patient outcomes.-
dc.languageeng-
dc.publisherBioMed Central Ltd. The Journal's web site is located at http://www.biomedcentral.com/bmccancer/-
dc.relation.ispartofBMC Cancer-
dc.rightsBMC Cancer. Copyright © BioMed Central Ltd.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectInflammatory response biomarker-
dc.subjectNomogram-
dc.subjectNon-small cell lung cancer-
dc.titleAn inflammation-related nomogram for predicting the survival of patients with non-small cell lung cancer after pulmonary lobectomy.-
dc.typeArticle-
dc.identifier.emailKam, NW: nwkam@hku.hk-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1186/s12885-018-4513-4-
dc.identifier.scopuseid_2-s2.0-85049062491-
dc.identifier.hkuros290321-
dc.identifier.volume18-
dc.identifier.issue1-
dc.identifier.spagearticle no. 692-
dc.identifier.epagearticle no. 692-
dc.identifier.isiWOS:000436613700004-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats